Shire gearing up for Vyvanse launch

Share this article:

Shire has amassed a 560-person sales force in advance of its Monday launch of new attention deficit hyperactivity drug Vyvanse.

Shire CEO Matthew Emmens said he is hopeful the drug will be able to capture 50% market share by early next decade.

"I have challenged my marketing and sales people," Emmens said in an interview with Reuters. "It's not a target. But it's an aspiration."

Emmens added that he is "very confident" Shire will be able to switch patients to the new drug from its top-selling Adderall XR, which at 30% is the current market leader among ADHD drugs. Adderall XR took in sales of $864 million in 2006 but faces patent expiration in 2009. Shire is banking on Vyvanse to take Adderall XR’s place.

Shire is expected to sell Vyvanse at $3.40 a day, around the same price as Adderall XR.
Emmens declined to forecast how quickly a switch might occur, but said analysts were expecting a similar pattern to the switch patients made to once-daily Adderall XR from its predecessor, Adderall, when 70% of patients converted in the first 18 months.

"In some ways the market is more favorable now than it was then," Emmens told Reuters noting that Adderall XR had only four months to become established before generic Adderall was launched. Adderall XR also faced competition from rival treatment, Johnson & Johnson’s Concerta. Vyvanse however is poised to get a boost in sales this fall when Concerta loses patent protection.
 
Vyvanse's selling point is that the drug is less open to abuse because it cannot be metabolized until it reaches the stomach.

Shire developed Vyvanse with New River Pharmaceuticals. Shire acquired New River in February in a deal worth $2.6 billion.

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...